Want to see IN:ALEMBICLTD full AI Analyst Report?

Alembic Limited (ALEMBICLTD) Price & Analysis

3 Followers

ALEMBICLTD Stock Chart & Stats

₹103.40

-₹1.48(-1.12%)

At close: Jan 09 4:00 PM EST

₹103.40

-₹1.48(-1.12%)

Day’s Range― - ―

52-Week Range₹70.64 - ₹117.91

Previous CloseN/A

Volume165.88K

Average Volume (3M)51.45K

Market Cap

₹22.49B

Enterprise Value₹17.32B

Total Cash (Recent Filing)₹980.38M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)7.0

Beta1.42

Next Earnings

Nov 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield2.74%

Share Statistics

EPS (TTM)12.48

Shares Outstanding256,781,830

10 Day Avg. Volume38,087

30 Day Avg. Volume51,453

Financial Highlights & Ratios

PEG Ratio2.67

Price to Book (P/B)0.74

Price to Sales (P/S)7.59

P/FCF Ratio17.23

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Steady Revenue GrowthThe multi-year increase in revenue indicates sustained expansion of the company’s pharmaceutical business rather than reliance on a single reporting period. Continued top-line growth can support investment in branded formulations, generics, APIs, and manufacturing capabilities over the coming quarters.

Conservative Balance SheetVery low leverage gives Alembic substantial financial resilience and reduces the burden of interest and refinancing obligations. A conservatively financed balance sheet preserves flexibility to fund operations, sustain investment, and withstand periods of uneven earnings or cash generation.

Improving Cash GenerationThe sharp improvement in operating and free cash flow strengthens the company’s ability to fund investment and meet obligations from internally generated resources. If maintained, stronger cash conversion would improve financial quality and provide greater flexibility across its pharmaceutical operations.

Bears Say

Operating Profitability DeclineThe decline in EBITDA and EBIT shows that recent revenue growth has not translated consistently into stronger operating profitability. Persistent pressure on operating earnings could reduce reinvestment capacity and weaken the durability of returns if the lower profit level continues.

Volatile Cash ConversionHistorically uneven operating and free cash flow makes the company’s earnings less dependable as a source of funding. Although 2026 improved materially, recurring volatility could complicate capital planning and leave results more exposed to working-capital or collection timing effects.

Earnings Quality ConcernThe unusual relationship between reported net income and revenue raises uncertainty about how much profitability is generated by the underlying pharmaceutical operations. Dependence on non-operating or one-off items could make earnings less repeatable and increase variability in future results.

Alembic Limited News

Alembic Limited Opens Special Window for Share Transfer Re-lodgement

Alembic Limited ( ($IN:ALEMBICLTD) ) has issued an announcement. Alembic Limited has announced a special window for the...

1y ago

Alembic Limited Updates Registrar Contact Details

Alembic Limited ( ($IN:ALEMBICLTD) ) has issued an announcement. Alembic Limited announced a change in the email and...

2y ago

ALEMBICLTD FAQ

What was Alembic Limited’s price range in the past 12 months?

Alembic Limited lowest stock price was ₹70.64 and its highest was ₹117.91 in the past 12 months.

What is Alembic Limited’s market cap?

Alembic Limited’s market cap is ₹22.49B.

When is Alembic Limited’s upcoming earnings report date?

Alembic Limited’s upcoming earnings report date is Nov 06, 2026 which is in 8 days.

How were Alembic Limited’s earnings last quarter?

Alembic Limited released its earnings results on Aug 11, 2026. The company reported ₹2.527 earnings per share for the quarter.

Is Alembic Limited overvalued?

According to Wall Street analysts Alembic Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alembic Limited pay dividends?

Alembic Limited pays a Annually dividend of ₹2.4 which represents an annual dividend yield of 2.74%. See more information on Alembic Limited dividends here

What is Alembic Limited’s EPS estimate?

Alembic Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Alembic Limited have?

Alembic Limited has 256,781,830 shares outstanding.

What happened to Alembic Limited’s price movement after its last earnings report?

Alembic Limited reported an EPS of ₹2.527 in its last earnings report. Following the earnings report the stock price went up 2.432%.

Which hedge fund is a major shareholder of Alembic Limited?

Currently, no hedge funds are holding shares in IN:ALEMBICLTD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Alembic Limited

Alembic Limited primarily manufactures and globally distributes active pharmaceutical ingredients (APIs) developed through both fermentation and chemical synthesis. The company operates across two distinct divisions: API and Real Estate. In its real estate ventures, Alembic undertakes the construction of residential and commercial properties, offers project management and marketing consultancy services, and leases commercial spaces. Furthermore, it operates its own power generation facilities, including co-generation plants with a total capacity of 11 MW and wind power plants contributing 5 MW. Founded in 1907 and headquartered in Vadodara, India, Alembic Limited is a subsidiary of Nirayu Limited.